Aureus Pharma
licenses AurWEB to Origenis
Paris,
FRANCE, September 2006 - Aureus Pharma a leading provider of
knowledge management solutions to accelerate discovery in the life
sciences industry, announces that Origenis, a Swiss-German based
company who offers creative services in drug design, synthesis and
characterization has become the first customer subscribing to its
AurWEB portal.
AurWEB allows
researchers to gain access to all of Aureus' knowledge databases,
which include AurSCOPE GPCR, Ion Channel, Kinase, ADME/Drug-Drug
interactions and hERG as well as the accompanying applications. All
are available via a highly secure web portal on a subscription
basis.
Origenis employs reliable, up-to-date knowledge bases to
incorporate relevant biological and pharmacological data into the
drug design process. Origenis uses proprietary methods to generate
predictive QSAR and QSPR models for its evolutionary design, and
creates pre-clinical compounds target and indication optimised
using a direct multi-objective approach. "With AurWEB the data
integration into MOREsystem® was straightforward" said Dr. Michael
Thormann, Managing Director of Origenis GmbH. "AurWeb represents a
valuable, exemplary data source. We use AurWeb to turn highly
relevant knowledge into powerful models for our technology
platform. This accelerates our drug discovery projects and improves
the quality of the resulting compounds."
"We are pleased to have Origenis join our growing list of
customers," said Dr. André Michel, CEO of Aureus Pharma. "AurWEB
with its flexible access to biological and chemical activity data
for important drug target families will complement Origenis
approach to discover novel target focussed drug
candidates."
About Aureus
Pharma
Aureus Pharma headquartered in Paris, France is a privately held
knowledge management based solutions provider for the life sciences
industry. Aureus Pharma accelerates new drug discovery by providing
knowledge databases which contain high quality quantitative
information for both chemistry and biology. Researchers gain rapid
access to knowledge for important drug target classes including
GPCR, Ion Channel, Kinase as well as other critical pharmaceutical
topics including ADME/Drug-Drug Interactions and the hERG Channel.
The information contained in the Aureus Pharma system is of primary
importance to aid in lead discovery and optimization as well as to
build predictive models. For further information on how Aureus
Pharma helps researchers turn data into discovery visit
www.aureus-pharma.com
Media Contact:
For Aureus Pharma:
Mary E. Donlan, Ph.D
Director of Marketing & Sales
+33 1 40 18 57 59/+33 6 76 19 51 77
mary.donlan@aureus-pharma.com
About
Origenis
Origenis (www.origenis.com) is a privately owned Swiss-German
company offering creative services for drug design, synthesis, and
characterisation. Its patented and validated technology platform -
MOREsystem® - is highly integrated, fast, and unparalleled.
Origenis employs sophisticated models for the directed target and
indication optimised exploitation of billions of novel compounds
through a proprietary multiparametric optimisation process to
deliver pre-clinical drug candidates with a priori defined
profiles. MOREsystem® has delivered several series of pre-clinical
compounds for a variety of targets and indications.
Media Contact:
For Origenis:
Dr. Michael Thormann
Managing Director
Tel. ++49 89 7801676-0
Fax. ++49 89 7801676-777
michael.thormann@origenis.de
Attachments: